S&P 500   4,195.94 (-0.23%)
DOW   32,940.03 (-0.46%)
QQQ   349.01 (+0.18%)
AAPL   177.04 (+0.92%)
MSFT   331.01 (-0.56%)
META   262.03 (+0.00%)
GOOGL   122.66 (-1.56%)
AMZN   121.06 (+0.79%)
TSLA   197.88 (+2.44%)
NVDA   400.10 (+2.73%)
NIO   7.40 (-3.90%)
BABA   78.31 (-3.29%)
AMD   125.44 (-1.25%)
T   15.60 (+0.65%)
F   12.62 (+4.38%)
MU   71.94 (-2.69%)
CGC   0.86 (-1.97%)
GE   101.89 (-0.83%)
DIS   87.16 (-1.28%)
AMC   4.58 (-1.29%)
PFE   37.06 (-1.44%)
PYPL   61.40 (+1.96%)
NFLX   388.73 (+2.60%)
S&P 500   4,195.94 (-0.23%)
DOW   32,940.03 (-0.46%)
QQQ   349.01 (+0.18%)
AAPL   177.04 (+0.92%)
MSFT   331.01 (-0.56%)
META   262.03 (+0.00%)
GOOGL   122.66 (-1.56%)
AMZN   121.06 (+0.79%)
TSLA   197.88 (+2.44%)
NVDA   400.10 (+2.73%)
NIO   7.40 (-3.90%)
BABA   78.31 (-3.29%)
AMD   125.44 (-1.25%)
T   15.60 (+0.65%)
F   12.62 (+4.38%)
MU   71.94 (-2.69%)
CGC   0.86 (-1.97%)
GE   101.89 (-0.83%)
DIS   87.16 (-1.28%)
AMC   4.58 (-1.29%)
PFE   37.06 (-1.44%)
PYPL   61.40 (+1.96%)
NFLX   388.73 (+2.60%)
S&P 500   4,195.94 (-0.23%)
DOW   32,940.03 (-0.46%)
QQQ   349.01 (+0.18%)
AAPL   177.04 (+0.92%)
MSFT   331.01 (-0.56%)
META   262.03 (+0.00%)
GOOGL   122.66 (-1.56%)
AMZN   121.06 (+0.79%)
TSLA   197.88 (+2.44%)
NVDA   400.10 (+2.73%)
NIO   7.40 (-3.90%)
BABA   78.31 (-3.29%)
AMD   125.44 (-1.25%)
T   15.60 (+0.65%)
F   12.62 (+4.38%)
MU   71.94 (-2.69%)
CGC   0.86 (-1.97%)
GE   101.89 (-0.83%)
DIS   87.16 (-1.28%)
AMC   4.58 (-1.29%)
PFE   37.06 (-1.44%)
PYPL   61.40 (+1.96%)
NFLX   388.73 (+2.60%)
S&P 500   4,195.94 (-0.23%)
DOW   32,940.03 (-0.46%)
QQQ   349.01 (+0.18%)
AAPL   177.04 (+0.92%)
MSFT   331.01 (-0.56%)
META   262.03 (+0.00%)
GOOGL   122.66 (-1.56%)
AMZN   121.06 (+0.79%)
TSLA   197.88 (+2.44%)
NVDA   400.10 (+2.73%)
NIO   7.40 (-3.90%)
BABA   78.31 (-3.29%)
AMD   125.44 (-1.25%)
T   15.60 (+0.65%)
F   12.62 (+4.38%)
MU   71.94 (-2.69%)
CGC   0.86 (-1.97%)
GE   101.89 (-0.83%)
DIS   87.16 (-1.28%)
AMC   4.58 (-1.29%)
PFE   37.06 (-1.44%)
PYPL   61.40 (+1.96%)
NFLX   388.73 (+2.60%)
NASDAQ:SNGX

Soligenix (SNGX) Stock Forecast, Price & News

$0.71
-0.02 (-2.07%)
(As of 01:58 PM ET)
Compare
Today's Range
$0.70
▼
$0.72
50-Day Range
$0.71
▼
$2.29
52-Week Range
$0.65
▼
$15.00
Volume
149,418 shs
Average Volume
551,475 shs
Market Capitalization
$2.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Soligenix MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
4.37% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of Soligenix in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($5.55) to ($3.06) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.12 out of 5 stars

See Top Rated MarketRank™ Stocks Here

SNGX stock logo

About Soligenix (NASDAQ:SNGX) Stock

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.

Receive SNGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Soligenix and its competitors with MarketBeat's FREE daily newsletter.

SNGX Stock News Headlines

May 30, 2023 | finance.yahoo.com
SNGX: Positive Results for Compatibility Study of HyBryte in CTCL
May 16, 2023 | finanznachrichten.de
Soligenix, Inc.: Soligenix Announces Recent Accomplishments And First Quarter 2023 Financial Results
May 30, 2023 | Edge On The Street (Ad)
The Graphite Shortage Story You're Not Being Told
Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.
May 16, 2023 | finance.yahoo.com
Soligenix Announces European Patent Grant for Use of Dusquetide in Oral Mucositis
May 15, 2023 | finance.yahoo.com
Soligenix Announces Recent Accomplishments And First Quarter 2023 Financial Results
May 11, 2023 | finance.yahoo.com
Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
May 9, 2023 | finance.yahoo.com
Soligenix Announces Closing of $8.5 Million Public Offering
May 5, 2023 | finance.yahoo.com
Soligenix Announces Pricing of $8.5 Million Public Offering
May 30, 2023 | Edge On The Street (Ad)
The Graphite Shortage Story You're Not Being Told
Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.
May 4, 2023 | finance.yahoo.com
Why Are Soligenix Shares Trading Higher Today
May 3, 2023 | finance.yahoo.com
Soligenix Announces Appointment of Timothy R. Coté, M.D. to its Board of Directors
May 1, 2023 | finance.yahoo.com
Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet's Disease
April 24, 2023 | finance.yahoo.com
SNGX: Planning for Second Phase 3 Study for HyBryte™ in CTCL…
April 24, 2023 | finance.yahoo.com
Soligenix Submits Type A Meeting Request to U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
April 14, 2023 | msn.com
Soligenix Shares Tumble as FDA Demands More Data
April 14, 2023 | msn.com
Soligenix stock sinks as FDA seeks additional positive results for cancer drug
April 14, 2023 | finance.yahoo.com
Soligenix Provides Regulatory Update on HyBryte™
April 5, 2023 | finance.yahoo.com
Soligenix Receives USAN Approval for "Hypericin Sodium" as Nonproprietary Name for Novel Active Ingredient in HyBryte™ and SGX302
April 5, 2023 | americanbankingnews.com
Soligenix, Inc. Expected to Earn Q1 2023 Earnings of ($1.25) Per Share (NASDAQ:SNGX)
April 3, 2023 | finance.yahoo.com
SNGX: Meeting with FDA to Discuss Refusal to File Letter…
April 3, 2023 | finance.yahoo.com
Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
March 31, 2023 | finance.yahoo.com
Soligenix Announces Recent Accomplishments And Year-End 2022 Financial Results
February 16, 2023 | finance.yahoo.com
Soligenix, Inc: Vital Vaccine Development Program has Potential to Address Future Marburg Virus Outbreaks
February 14, 2023 | investorplace.com
Why Is Soligenix (SNGX) Stock Down 27% Today?
February 14, 2023 | investorplace.com
Why Is Soligenix (SNGX) Stock Down 35% Today?
February 14, 2023 | prnewswire.com
Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
February 9, 2023 | finance.yahoo.com
Soligenix Announces Reverse Stock Split
See More Headlines
Receive SNGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Soligenix and its competitors with MarketBeat's FREE daily newsletter.

SNGX Company Calendar

Last Earnings
11/12/2021
Today
5/30/2023
Next Earnings (Estimated)
8/11/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SNGX
CUSIP
N/A
CIK
812796
Web
www.soligenix.com
Phone
(609) 538-8200
Fax
609-452-6467
Employees
13
Year Founded
1987

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-13,800,000.00
Net Margins
-996.96%
Pretax Margin
-1,218.01%
Return on Equity
-589.84%
Return on Assets
-64.89%

Debt

Debt-to-Equity Ratio
6.67
Current Ratio
0.94
Quick Ratio
0.94

Sales & Book Value

Annual Sales
$950,000.00
Price / Sales
2.27
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.85) per share
Price / Book
-0.85

Miscellaneous

Outstanding Shares
2,980,000
Free Float
2,857,000
Market Cap
$2.16 million
Optionable
Not Optionable
Beta
1.74

Social Links


Key Executives

  • Christopher J. SchaberChristopher J. Schaber
    Chairman, President & Chief Executive Officer
  • Jonathan L. GuarinoJonathan L. Guarino
    Chief Financial Officer, Secretary & Senior VP
  • Oreola Donini
    Chief Scientific Officer & Senior Vice President
  • Richard C. Straube
    Chief Medical Officer & Senior Vice President
  • Adam T. Rumage
    VP-Regulatory Affairs & Project Management

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













SNGX Stock - Frequently Asked Questions

How have SNGX shares performed in 2023?

Soligenix's stock was trading at $0.4520 at the start of the year. Since then, SNGX stock has increased by 60.4% and is now trading at $0.7250.
View the best growth stocks for 2023 here.

Are investors shorting Soligenix?

Soligenix saw a increase in short interest in May. As of May 15th, there was short interest totaling 350,100 shares, an increase of 63.0% from the April 30th total of 214,800 shares. Based on an average daily trading volume, of 835,000 shares, the short-interest ratio is presently 0.4 days. Approximately 4.4% of the shares of the stock are sold short.
View Soligenix's Short Interest.

When is Soligenix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our SNGX earnings forecast.

How were Soligenix's earnings last quarter?

Soligenix, Inc. (NASDAQ:SNGX) announced its earnings results on Friday, November, 12th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.03. The biopharmaceutical company had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.80 million. Soligenix had a negative net margin of 996.96% and a negative trailing twelve-month return on equity of 589.84%.

What other stocks do shareholders of Soligenix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Soligenix investors own include VBI Vaccines (VBIV), T2 Biosystems (TTOO), Trevena (TRVN), Vaxart (VXRT), OPKO Health (OPK), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Actinium Pharmaceuticals (ATNM).

What is Soligenix's stock symbol?

Soligenix trades on the NASDAQ under the ticker symbol "SNGX."

Who are Soligenix's major shareholders?

Soligenix's stock is owned by a number of retail and institutional investors. Top institutional shareholders include First Wilshire Securities Management Inc. (0.78%) and Geode Capital Management LLC (0.73%). Insiders that own company stock include Christopher J Schaber, Jerome B Zeldis, Jonathan L Guarino and Richard Straube.
View institutional ownership trends.

How do I buy shares of Soligenix?

Shares of SNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Soligenix's stock price today?

One share of SNGX stock can currently be purchased for approximately $0.73.

How much money does Soligenix make?

Soligenix (NASDAQ:SNGX) has a market capitalization of $2.16 million and generates $950,000.00 in revenue each year.

How can I contact Soligenix?

Soligenix's mailing address is 29 EMMONS DRIVE SUITE B-10, PRINCETON NJ, 08540. The official website for the company is www.soligenix.com. The biopharmaceutical company can be reached via phone at (609) 538-8200, via email at ir@soligenix.com, or via fax at 609-452-6467.

This page (NASDAQ:SNGX) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -